Adenovirus Vector Vaccine Platform

MilliporeSigma and the University of Oxford, Jenner Institute have entered into a collaboration to advance the development of a rapid, scalable and GMP compliant process for simian adenoviruses used as a vector for vaccines against infectious diseases such as rabies and emerging threats like Zika and Ebola. This work aimed at the transition from a labor and time intensive process development to a process platform utilizing disposable technologies and novel purification techniques. This collaboration was formed to achieve defined productivity target and to develop a platform for various adenovirus serotypes used at the Institute.

Learn more about the GMP transferable process for adenovirus vector-based vaccines manufacturing that was successfully developed with Jenner Institute.